New insights into innate immune control of systemic candidiasis

Medical Mycology

Volumn 52, Issue 6, 2014, Pages 555-564

  Lionakis, Michail S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

innate immunity; monocytes macrophages; neutrophils; systemic candidiasis

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA; CELL SPECIFICITY; DENDRITIC CELL; GRANULOCYTE; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; INVASIVE CANDIDIASIS; MACROPHAGE; MONOCYTE; MONONUCLEAR PHAGOCYTE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; ANIMAL; CANDIDIASIS; DISEASE MODEL; IMMUNOLOGY; MOUSE;

ANIMALS; CANDIDA; CANDIDIASIS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; MICE;

EID: 84905050213     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myu029     Document Type: Review

References (107)

1. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
2. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
3. Miller LG, Hajjeh RA, Edwards JE, Jr. Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis 2001; 32: 1110.
4. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26-34.
5. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61 Suppl 1: 19-30.
6. Center for Disease Control and Prevention. http://www.cdc.gov/hiv/ statistics/basics/.html
7. Center for Disease Control and Prevention. http://wwwnc.cdc.gov/eid/ article/13/12/07-0629-article.htm.html
8. Louria DB, Stiff DP, Bennett B. Disseminated moniliasis in the adult. Medicine 1962; 41: 307-338.
9. Abe F, Tateyama M, Shibuya H, Azumi N, Ommura Y. Disseminated fungal infection. A review of 20 autopsy cases. Acta Pathol Jpn 1984; 34: 1201-1208.
10. Clemons KV, Gonzalez GM, Singh G et al. Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother 2006; 50: 2650-2657.
11. Koh AY, Köhler JR, Coggshall KT, Van Rooijen N, Pier GB. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog. 2008; 4: e35.
12. Spellberg B, Ibrahim AS, Edwards JE, Jr, Filler SG. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 2005; 192: 336-343.
13. Bodey GP, Nies BA, Freireich EJ. Multiple organism septicemia in acute leukemia; analysis of 54 episodes. Arch Intern Med 1965; 116: 266-72.
14. Preisler HD, Hasenclever HF, Levitan AA, Henderson ES. Serologic diagnosis of disseminated candidiasis in patients with acute leukemia. Ann Intern Med 1969; 70: 19-30.
15. Samonis G, Gikas A, Anaissie EJ et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37: 51-53.
16. Zelante T, Iannitti RG, Cunha C et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39: 372-385.
17. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969; 1: 598-599.
18. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
19. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007; 54: 521-529.
20. Sabesin SM. Renal failure and disseminated candidiasis. Arch Intern Med 1962; 110: 526-534.
21. Lionakis MS, Lim JK, Lee CC, Murphy PM. Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun 2011; 3: 180-199.
22. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6: 67-78.
23. Brown GD. Innate antifungal immunity: the key role of phagocytes. Annu Rev Immunol 2011; 29: 1-21.
24. Tsoni SV, Kerrigan AM, Marakalala MJ et al. Complement C3 plays an essential role in the control of opportunistic fungal infections. Infect Immun 2009; 77: 3679-3685.
25. Mullick A, Elias M, Picard S et al. Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infect Immun 2004; 72: 5868-5876.
26. Villamón E, Gozalbo D, Roig P et al. Toll-like receptor-2 is essential in murine defenses against Candida albicans infections. Microbes Infect 2004; 6: 1-7.
27. Netea MG, Van Der Graaf CA, Vonk AG et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185: 1483-1489.
28. Biondo C, Malara A, Costa A et al. Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis. Eur J Immunol. 2012; 42: 2632-2643.
29. Marr KA, Balajee SA, Hawn TR et al. Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun 2003; 71: 5280-5286.
30. Taylor PR, Tsoni SV, Willment JA et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007; 8: 31-38.
31. Saijo S, Ikeda S, Yamabe K et al. Dectin-2 recognition of alphamannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010; 32: 681-691.
32. Zhu LL, Zhao XQ, Jiang C et al. C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity 2013; 39: 324-334.
33. Wells CA, Salvage-Jones JA, Li X et al. The macrophageinducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans. J Immunol 2008; 180: 7404-7413.
34. Gross O, Gewies A, Finger K et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006; 442: 651-656.
35. Pietrella D, Pandey N, Gabrielli E et al. Secreted aspartic proteases of Candida albicans activate the NLRP3 inflammasome. Eur J Immunol 2013; 43: 679-692.
36. Gringhuis SI, Kaptein TM, Wevers BA et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1βvia a noncanonical caspase-8 inflammasome. Nat Immunol 2012; 13: 246-254.
37. Gross O, Poeck H, Bscheider M et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defense. Nature 2009; 459: 433-436.
38. Joly S, Eisenbarth SC, Olivier AK et al. Cutting edge: Nlrp10 is essential for protective antifungal adaptive immunity against Candida albicans. J Immunol 2012; 189: 4713-4717.
39. Netea MG, Gow NA, Munro CA et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. JClin Invest 2006; 116: 1642-1650.
40. Jouault T, El Abed-El Behi M, Martínez-Esparza M et al. Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J Immunol 2006; 177: 4679-4687.
41. Cheng SC, Sprong T, Joosten LA et al. Complement plays a central role in Candida albicans-induced cytokine production by human PBMCs. Eur J Immunol 2012; 42: 993-1004.
42. Dennehy KM, Willment JA, Williams DL, Brown GD. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur J Immunol 2009; 39: 1379-1386.
43. Sousa Mda G, Reid DM, Schweighoffer E et al. Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe 2011; 9: 436-443.
44. Sato K, Yang XL, Yudate T et al. Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses. J Biol Chem 2006; 281: 38854-38866.
45. Robinson MJ, Osorio F, Rosas M et al. Dectin-2 is a Sykcoupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med 2009; 206: 2037-2051.
46. Goodridge HS, Shimada T, Wolf AJ et al. Differential use of CARD9 by dectin-1 in macrophages and dendritic cells. J Immunol 2009; 182: 1146-1154.
47. Netea MG, Gow NA, Joosten LA et al. Variable recognition of Candida albicans strains by TLR4 and lectin recognition receptors. Med Mycol 2010; 48: 897-903.
48. Wheeler RT, Kombe D, Agarwala SD, Fink GR. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog 2008; 4: e1000227.
49. Marakalala MJ, Vautier S, Potrykus J et al. Differential adaptation of Candida albicans in vivo modulates immune recognition by dectin-1. PLoS Pathog 2013; 9: e1003315.
50. Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states and associated infections. Mol Immunol 2011; 48: 1643-1655.
51. von Bernuth H, Picard C, Jin Z et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321: 691-696.
52. Glocker EO, Hennigs A, Nabavi M et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361: 1727-1735.
53. Drewniak A, Gazendam RP, Tool AT et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013; 121: 2385-2392.
54. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. NEngl J Med 2009; 361: 1760-1767.
55. Yu Y, Du L, Yuan T et al. Risk factors and clinical analysis for invasive fungal infection in neonatal intensive care unit patients. Am J Perinatol 2013; 30: 589-594.
56. Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-1078.
57. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32: 1713-1717.
58. Lionakis MS, Netea MG. Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog 2013; 9: e1003079.
59. Ermert D, Niemiec MJ, Röhm M et al. Candida albicans escapes from mouse neutrophils. J Leukoc Biol 2013; 94: 223-236.
60. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79: 170-200.
61. Brothers KM, Newman ZR, Wheeler RT. Live imaging of disseminated candidiasis in zebra fish reveals role of phagocyte oxidase in limiting filamentous growth. Eukaryot Cell 2011; 10: 932-944.
62. Brothers KM, Gratacap RL, Barker SE et al. NADPH oxidasedriven phagocyte recruitment controls Candida albicans filamentous growth and prevents mortality. PLoS Pathog 2013; 9: e1003634.
63. Reeves EP, LuH, Jacobs HL et al. Killing activity of neutrophils is mediated through activation of proteases by K+flux. Nature 2002; 416: 291-297.
64. Aratani Y, Koyama H, Nyui S et al. Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect Immun 1999; 67: 1828-1836.
65. Lehrer RI, Cline MJ. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 1969; 48: 1478-1488.
66. Lehrer RI. Measurement of candidacidal activity of specific leukocyte types in mixed cell populations I. Normal, myeloperoxidase-deficient, and chronic granulomatous disease neutrophils. Infect Immun 1970; 2: 42-47.
67. Cech P, Papathanassiou A, Boreux G, Roth P, Miescher PA. Hereditary myeloperoxidase deficiency. Blood 1979; 53: 403-411.
68. Winkelstein JA, Marino MC, Johnston RB, Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155-169.
69. Lionakis MS. Genetic susceptibility to fungal infections in humans. Curr Fungal Infect Rep 2012; 6: 11-22.
70. Lehrer RI. Functional aspects of a second mechanism of candidacidal activity by human neutrophils. J Clin Invest 1972; 51: 2566-2572.
71. Greenblatt MB, Aliprantis A, Hu B, Glimcher LH. Calcineurin regulates innate antifungal immunity in neutrophils. J Exp Med 2010; 207: 923-931.
72. Li X, Utomo A, Cullere X et al. The β-glucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to promote Candida albicans clearance. Cell Host Microbe 2011; 10: 603-615.
73. Urban CF, Reichard U, Brinkmann V, Zychlinsky A. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol. 2006; 8: 668-676.
74. Metzler KD, Fuchs TA, Nauseef WM et al. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood 2011; 117: 953-959.
75. Kawakami T, He J, Morita H et al. Rab27a Is essential for the formation of neutrophil extracellular traps (NETs) in neutrophil-like differentiated HL60 cells. PLoS One 2014; 9: e84704.
76. Byrd AS, O'Brien XM, Johnson CM, Lavigne LM, Reichner JS. An extracellular matrix-based mechanism of rapid neutrophil extracellular trap formation in response to Candida albicans. J Immunol 2013; 190: 4136-4148.
77. Urban CF, Ermert D, Schmid M et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009; 5: e1000639.
78. Bachelerie F, Ben-Baruch A, Burkhardt AM et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2013; 66: 1-79.
79. Lin L, Ibrahim AS, Xu X et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5: e1000703.
80. Schmidt CS, White CJ, Ibrahim AS et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012; 30: 7594-7600.
81. Romani L, Mencacci A, Cenci E et al. An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol 1997; 158: 2356-2362.
82. Gargan RA, Hamilton-Miller JM, Brumfitt W. Effect of pH and osmolality on in vitro phagocytosis and killing by neutrophils in urine. Infect Immun 1993; 61: 8-12.
83. Hampton MB, Chambers ST, Vissers MC, Winterbourn CC. Bacterial killing by neutrophils in hypertonic environments. J Infect Dis 1994; 169: 839-846.
84. Lionakis MS, Fischer BS, Lim JK et al. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog 2012; 8: e1002865.
85. Tomashefski JF Jr, Abramowsky CR. Candida-associated renal papillary necrosis. Am J Clin Pathol 1981; 75: 190-194.
86. Karlowicz MG. Candidal renal and urinary tract infection in neonates. Semin Perinatol 2003; 27: 393-400.
87. Legrand F, Lecuit M, Dupont B et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46: 696-702.
88. Qian Q, Jutila MA, Van Rooijen N, Cutler JE. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol 1994; 152: 5000-5008.
89. Ngo LY, Kasahara S, Kumasaka DK et al. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J Infect Dis 2014; 209: 109-119.
90. Lionakis MS, Swamydas M, Fischer BG et al. CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest 2013; 123: 5035-5051.
91. ++ monocytes, promote Th17 responses to Candida albicans. Eur J Immunol 2011; 41: 2915-2924.
92. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010; 10: 453-460.
93. Kawakami T, Lichtnekert J, Thompson LJ et al. Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions. J Immunol 2013; 191: 3358-3372.
94. Vinh DC, Patel SY, Uzel G et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115: 1519-1529.
95. Hsu AP, Sampaio EP, Khan J et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118: 2653-2655.
96. Hambleton S, Salem S, Bustamante J et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365: 127-138.
97. Bär E, Whitney PG, Moor K et al. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 2014; 40: 117-127.
98. Voigt J, Hünniger K, Bouzani M et al. Human NK cells act as phagocytes against Candida albicans and mount an inflammatory response which modulates neutrophil antifungal activity. J Infect Dis 2014; 209: 616-626.
99. Li SS, Kyei SK, Timm-McCann M et al. The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK Cells from HIV-infected patients. Cell Host Microbe 2013; 14: 387-397.
100. Jouanguy E, Gineau L, Cottineau J et al. Inborn errors of the development of human natural killer cells. Curr Opin Allergy Clin Immunol 2013; 13: 589-595.
101. Tarumoto N, Kinjo Y, Ueno K et al. A limited role of iNKT cells in controlling systemic Candida albicans infections. Jpn J Infect Dis 2012; 65: 522-526.
102. Cohen NR, Tatituri RV, Rivera A et al. Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 2011; 10: 437-450.
103. Tarumoto N, Kinjo Y, Kitano N et al. Exacerbation of Invasive Candida albicans infection by commensal bacteria or a glycolipid through IFN-γ produced in part by iNKT cells. J Infect Dis. 2013
104. Szabo EK, Maccallum DM. A novel renal epithelial cell in vitro assay to assess Candida albicans virulence. Virulence. 2014; 5: 286-296.
105. De Luca A, Zelante T, D'Angelo C et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010; 3: 361-373.
106. Filler SG, Sheppard DC. Fungal invasion of normally nonphagocytic host cells. PLoS Pathog 2006; 2: e129.
107. Voisin MB, Nourshargh S. Neutrophil transmigration: emergence of an adhesive cascade within venular walls. J Innate Immun 2013; 5: 336-547.